Fertility and Sterility
Volume 79, Issue 3 , Pages 562-566 , March 2003

Effect of rosiglitazone on spontaneous and clomiphene citrate–induced ovulation in women with polycystic ovary syndrome

Presented at the Annual Meeting of the American Society of Reproductive Medicine, Orlando, Florida, October 21–25, 2001.

  • Ghina Ghazeeri, M.D.

      Affiliations

    • Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, Memphis, Tennessee, USA
    • ,
  • William H Kutteh, M.D.

      Affiliations

    • Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, Memphis, Tennessee, USA
    • ,
  • Michael Bryer-Ash, M.D.

      Affiliations

    • Gonda Diabetes Center, Department of Medicine, University of California, Los Angeles School of Medicine, Los Angeles, California, USA
    • ,
  • Derek Haas, M.D.

      Affiliations

    • Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, Memphis, Tennessee, USA
    • ,
  • Raymond W Ke, M.D.

      Affiliations

    • Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, Memphis, Tennessee, USA
    • Corresponding Author InformationReprint requests: Raymond W. Ke, M.D., Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, 956 Court Avenue Room D-328, Memphis, Tennessee 38163, USA (FAX: 901-448-8782).

Received 15 April 2002 ,Revised 15 November 2002 ,Accepted 15 November 2002.

References 

  1. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab. 1987;65:499–507
  2. Dale PO, Tanto P, Vaaler S. Body weight, hyperinsulinemia and gonadotropin level in PCOS (evidence of two distinct populations). Fertil Steril. 1992;58:487–491
  3. Nestler JE, Barlascini CO, Matt DW, Steingold KA, Plymate SR, Clore JN, et al.  Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 1989;68:1027–1032
  4. Nestler J, Jakubowicz LD, Evans W, Pasquali R. Effective metformin on spontaneous and clomiphene induced ovulation in PCOS. N Engl J Med. 1998;338:1876–1880
  5. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 1985;61:946–951
  6. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, et al.  Coronary heart disease risk factors in women with polycystic ovarian syndrome. Arterioscler Thromb Vasc Biol. 1995;15:821–826
  7. Hasegawa I, Murakawa H, Suzuki M, Yamamoto Y, Kurabayashi T, Tanaka K. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril. 1999;71:323–327
  8. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, et al.  Activators of peroxisome proliferator-activated receptor-γ have depot-specific effects on human preadipocyte differentiation. J Clin Invest. 1997;100:3149–3153
  9. Lehmann JM, Moore LB, Smith-Oliver TA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma. J Biol Chem. 1995;270:12953–12956
  10. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83:2694–2698
  11. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. JAMA. 2000;283:1695–1702
  12. Ehrmann D, Schneider D, Sobel B, Cavaghan M, Imperial J, Rosenfield R, et al.  Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinal lysis in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 1997;82:2108–2116
  13. Dunaif A, Scott D, Finegood D, Quinates B, Whitecomb R. The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovarian syndrome. J Clin Endocrinol Metab. 1996;81:3299–3306
  14. Barbieri RL, Makris A, Randall RW, Daniells G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 1986;62:904–910
  15. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modifications in obese polycystic ovary syndrome (role of insulin sensitivity and luteinizing hormone). J Clin Endocrinol Metab. 1999;84:1470–1474
  16. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, et al.  Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998;338:867–872
  17. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:524–530
  18. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovarian syndrome who are resistant to clomiphene citrate alone. Fertil Steril. 2001;75:310–315
  19. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, et al.  Troglitazone improves ovulation and hirsutism in the polycystic ovarian syndrome (a multicenter, double-blind, placebo-controlled trial). J Clin Endocrinol Metab. 2001;86:1626–1632
  20. Saltiel A, Olefsky J. Thiazolidinediones in the treatment of insulin resistance in type II diabetes. Diabetes. 1996;45:166–169
  21. Day C. Thiazolidinediones (a new class of antidiabetic drugs). Diabet Med. 1999;16:179–192
  22. Shimuzu H, Tsuchiya T, Sato N, Shimomura Y, Kobayashi I, Mori M. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care. 1998;21:1470–1474
  23. Avandia drug insert. In Physicians Drug Reference 2001

☆ Supported in part by U.S. Public Health Services Grant #MOIRR00211.

PII: S0015-0282(02)04843-4

doi: 10.1016/S0015-0282(02)04843-4

Fertility and Sterility
Volume 79, Issue 3 , Pages 562-566 , March 2003

Article Tools